MORRISVILLE, N.C., Oct. 13, 2017 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, October 18, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States and Canada) or +1 (703) 318-2240 (international). The conference ID for the live call is 1458576. A live webcast will be accessible from the Events page of the Company’s website at http://Events.Novan.com. The webcast will be archived on the Company’s website for 7 days following the live call.
About Novan
Novan, Inc. is a pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We have advanced programs with four product candidates for dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases.
For more information, visit the Company’s website at www.Novan.com.
CONTACT:
(Investors)
Novan, Inc.
919-627-6847
[email protected]
(Media)
Deb Holliday
Pascale Communications, LLC
412-877-4519
[email protected]


Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 



